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Background: With the advent of sodium glucose co-transporter 2 inhibitors to control glu-
cose and treat diabetes, laboratory data aided by either timed or spot glucose levels in the 
urine could be used as an alternative marker of drug response. The aim of this study was 
to assess the agreement between overnight urinary glucose excretion (UGE) and morning 
spot urinary glucose-to-creatinine ratio (UGCR).
Methods: In this prospective cross-sectional study, we enrolled a total of 215 participants 
with either normal glucose tolerance (NGT), pre-diabetes, or type 2 diabetes mellitus (T2DM). 
To exclude external factors such as food intake and physical activity, urine samples col-
lected overnight at an 8-hr interval and the first-voided morning spot urine were collected 
and compared.
Results: The median values of overnight 8-hr UGE in participants with NGT (N=14), pre-
diabetes (N=41), and T2DM (N=160) were 35.0 mg, 35.6 mg, and 653.4 mg, respec-
tively. In participants with T2DM, the median values of overnight 8-hr UGCR and first-voided 
morning spot UGCR (M-UGCR) were 1.37 mg/mg and 0.16 mg/mg, respectively. Quanti-
tative analyses using an intraclass correlation coefficient (ICC) demonstrated a good reli-
ability of measurement of the overnight 8-hr UGCR and M-UGCR (ICC=0.943, P <0.001). 
The M-UGCR was also significantly related to the overnight 8-hr UGE (r=0.828, P <0.001).
Conclusions: M-UGCR and overnight 8-hr UGCR showed good agreement, suggesting 
that M-UGCR be used as a simple index for estimating overnight amounts of UGE in pa-
tients with T2DM.
Key Words: Type 2 diabetes mellitus, Urinary glucose excretion, Urinary glucose-to-creati-
nine ratio
Received: May 15, 2016
Revision received: June 20, 2016
Accepted: September 28, 2016
Corresponding author: Byung-Wan Lee
Department of Internal Medicine, Yonsei 
University College of Medicine, 50-1, 





* These authors contributed equally to this 
work.
© The Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
INTRODUCTION
Glycosuria, the excretion of glucose in the urine, nearly always 
results from elevated plasma glucose levels, except for rare ab-
normalities in glucose reabsorption within the tubules. Elevated 
urine glucose concentration therefore indicates either the pres-
ence of hyperglycemia or a defect in tubular function [1]. Diag-
nosing diabetes or monitoring glycemic control by assessing the 
amount of urinary glucose has been replaced by more reliable 
and accurate blood or plasma glycemic indices. Glycated hemo-
globin (HbA1c) levels, commonly used as the gold standard for 
glycemic index, exhibit a fairly good correlation with fasting plasma 
glucose in a single specimen and 24-hr urinary glucose secre-
tion [2-4], which in turn helps to achieve target glycemic goals.
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The recent advent of sodium-glucose co-transporter 2 (SGLT2) 
inhibitors, which prevent glucose reabsorption from renal proxi-
mal tubules, promoting urinary glucose excretion (UGE) and 
decreasing plasma glucose levels [5], adds to the wide range of 
pharmacotherapeutic options for treating patients with diabetes. 
Considering the pharmacokinetics of SGLT2 inhibitors, during 
the use of these drugs in diabetic patients, the traditional posi-
tive relationship between levels of blood or plasma glycemic in-
dices and the concentration or amount of secreted urinary glu-
cose cannot be applied. The pharmacological effects of SGLT2 
inhibitors include increased UGE and improvements in blood 
glucose indices [6, 7]. Therefore, collecting and assessing either 
timed or spot glucose levels in the urine in conjunction with 
HbA1c levels might be of use as an alternative marker of drug 
response when prescribing an SGLT2 inhibitor for glycemic con-
trol. A 24-hr urine collection, however, can be bothersome to 
perform and is largely influenced by food intake. In contrast, 
overnight urine collections might exclude external factors, such 
as food intake, and solely be influenced by renal gluconeogene-
sis in the post-absorptive state [8]. Nevertheless, no published 
data address whether glucose in a morning spot urine collection 
reflects the total amount of glucose excretion during the over-
night period. 
In this study, we aimed to investigate whether the first voided 
morning spot urinary glucose-to-creatinine ratio (M-UGCR) can 
predict overnight 8-hr urinary glucose-to-creatinine ratio (UGCR), 
and determine correlations between overnight UGE and other 




In this prospective cross-sectional study, we enrolled participants 
with either normal glucose levels, pre-diabetes, or T2DM, who 
had newly visited the Severance Hospital Diabetes Center be-
tween May 2014 and May 2015. Participants who met the fol-
lowing criteria were excluded: 1)<20 or ≥80 yr of age; 2) hav-
ing type 1 diabetes; 3) organ transplantation recipients; 4) esti-
mated glomerular filtration rate (eGFR)<60 mL/min/1.73 m2; 5) 
currently taking an SGLT2 inhibitor; and 6) pregnant wo men. We 
classified participants into three groups: those with normal glu-
cose tolerance (NGT), pre-diabetes, and T2DM. NGT was de-
fined as a fasting plasma glucose<5.6 mmol/L and HbA1c <5.7% 
(38.8 mmol/mol). Pre-diabetes was defined as a fasting plasma 
glucose of 5.6-6.9 mmol/L or HbA1c of 5.7-6.4% (38.8-46.4 
mmol/mol). T2DM was defined on the basis of 1) the participant’s 
use of insulin or oral hypoglycemic agents, 2) fasting plasma 
glucose ≥7.0 mmol/L, or 3) HbA1c ≥6.5% (47.5 mmol/mol). A 
total of 215 participants (mean age 55±13 yr) were enrolled in 
this study. Baseline demographic and laboratory characteristics 
of the participants are shown in Table 1. The age and gender 
distributions were similar among the three groups. In the group 
with T2DM, the average duration of diabetes and HbA1c were 
5.8±6.6 yr and 7.45 (6.70-9.00)% (57.9 [49.7-74.9] mmol/ mol), 
respectively, and basal and stimulated insulin and C-peptide 
levels did not significantly differ between the groups. The post-
prandial C-peptide-to-glucose ratio (PCGR) value, a well-vali-
dated marker of insulin secretory function, significantly decre-
ased in the T2DM group (2.23 [1.36-3.54]), compared with the 
NGT and pre-diabetes groups (3.76 [2.92-5.58] and 3.99 [3.33-
5.41], respectively, P <0.001). The values of homeostatic model 
assessment of insulin resistance (HOMA-IR) increased with in-
creasing severity of diabetes status (1.06 [0.82-1.72], 1.76 [1.31-
3.38], and 2.76 [1.68-5.09], respectively, P <0.001). Kidney 
function indices were not significantly different between groups. 
Written informed consent was obtained from all participants be-
fore the study, and the Ethics Committee of the Yonsei Univer-
sity College of Medicine approved the study protocol (4-2014-
0220).
2. Measurements of blood glucometabolic parameters
After overnight fasting, blood samples were collected before (0 
min; designated as basal) and after (90 min; designated as sti-
mulated) ingestion of a standardized mixed-meal (Mediwell Dia-
betic Meal, [Maeil Dairies Co., Yeongdong-gun, Chungbuk, Ko-
rea] 2 cans; total 400 mL, 400 kcal, 18 g fat, 44 g carbohydrate, 
and 20 g protein) to measure glucose, insulin/C-peptide, and 
other parameters. Pancreatic beta cell function and insulin sen-
sitivity were assessed by using the following indices [9]: Homeo-
static model assessment of pancreatic β-cell function (HOMA-β) 
=[(basal insulin [pM]×0.48)/(basal glucose [mM]-3.5)]; HOMA-
IR=[(basal insulin [pM] × glucose [mM]) / 156.3]; C-peptide 
increment (∆C-peptide=[stimulated C-peptide (pmol/mL)-basal 
C-peptide (pmol/mL)]; and insulin increment (∆insulin=[stimul-
at ed insulin (pmol/L)-basal insulin (pmol/L)]. PCGR was defined 
as follows [10]: [(stimulated C-peptide [ng/mL]/stimulated glu-
cose [mg/dL])×100]. The eGFR was derived from the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) creati-
nine-based equation [11]. HbA1c was measured by using an 
immunoassay on an Integra 800 CTS instrument (Roche, Her-
cules, CA, USA). Serum glycated albumin (GA) levels were de-
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termined by an enzymatic method (LUCICA GA-L, Asahi Kasei 
Pharma Co., Tokyo, Japan), by using a Hitachi 7600 P module 
auto-analyzer (Hitachi Instruments Service, Tokyo, Japan). Se-
rum insulin and C-peptide were measured by an electrochemi-
luminescence immunoassay with a Cobas 600 e501 analyzer 
(Roche Diagnostics, Basel, Switzerland). Urine glucose level was 
measured by the hexokinase method, by an AU680 chemistry 
analyzer (Beckman Coulter, Brea, CA, USA).
3. Measurements of urinary glucometabolic parameters
To exclude external factors like food intake on glucose homeo-
stasis, participants were advised to fast after dinner, except for 
water, and an overnight 8-hr urine sample from bedtime (ap-
proximately 10 P.M.) to the first-voided morning urine was col-
lected. An 8-10-mL urine volume from the first-voided morning 
urine was separately collected for the first-voided morning spot 
urine analysis (See Supplemental Data Figure S1). The sam-
pling day for the morning urine was the same one as for blood 
sampling for the standardized mixed-meal tolerance test. Uri-
Table 1. Baseline demographic and laboratory characteristics of participants
Baseline characteristics








   Age (yr) 48.2±15.0 53.2±12.4 55.4±12.4 0.078
   Men, n (%) 7 (53.3) 20 (47.6) 88 (54.7) 0.715
   Duration of diabetes (yr) 5.80±6.60
Antidiabetic drug use  
   No, n (%) 66 (41.3)
   Metformin, n (%) 64 (40.0)
   Insulin, n (%) 14 (8.8)
Glycemic indices
   Basal glucose (mmol/L) 5.14 (4.96-5.29) 6.00 (5.58-6.53) 7.92 (6.79-10.1) <0.001
   Stimulated glucose (mmol/L) 6.44 (5.15-6.89) 7.78 (6.53-8.72) 12.0 (9.65-14.3) <0.001
   Glycated albumin (%) 13.1 (12.2-14.0) 14.0 (13.0-15.3) 19.0 (16.0-24.0) <0.001
   HbA1C (%) 5.60 (5.50-5.83) 5.80 (5.63-6.00) 7.45 (6.70-9.00) <0.001
   HbA1C (mmol/mol) 37.7 (36.6-40.2) 39.9 (38.0-42.1) 57.9 (49.7-74.9) <0.001
Urinary glycemic indices
   Overnight 8-hr UGE (mg) 35.0 (21.7-63.8) 35.6 (22.7-84.6)  653.4 (53.6-9136.5) <0.001
   Overnight 8-hr UGCR (mg/mg) 0.06 (0.04-0.08) 0.07 (0.05-0.16) 1.37 (0.10-21.4) <0.001
   M-UGCR (mg/mg) 0.05 (0.04-0.07) 0.06 (0.04-0.08) 0.16 (0.07-8.01) <0.001
Insulin secretory/resistant indices
   Basal insulin (pmol/L) 28.3 (21.0-46.2) 36.5 (30.0-73.4) 43.1 (28.9-71.4) 0.102
   Stimulated insulin (pmol/L) 125.7 (88.1-302.2) 241.6 (153.5-310.3) 174.9 (108.5-306.4) 0.072
   Basal C-peptide (nmol/L) 0.55 (0.43-0.72) 0.67 (0.53-0.91) 0.72 (0.55-0.99) 0.056
   Stimulated C-peptide (nmol/L) 1.36 (1.00-2.26) 1.81 (1.53-2.28) 1.50 (1.18-2.13) 0.049
   ∆Insulin (pmol/L) 105.3 (63.8-268.5) 188.6 (116.9-240.4) 118.6 (68.0-238.2) 0.052
   ∆C-peptide (nmol/L) 0.86 (0.55-1.54) 1.10 (0.89-1.56) 0.77 (0.45-1.34) 0.011
   PCGR 3.76 (2.92-5.58) 3.99 (3.33-5.41) 2.23 (1.36-3.54) <0.001
   HOMA-IR 1.06 (0.82-1.72) 1.76 (1.31-3.38) 2.76 (1.68-5.09) <0.001
   HOMA-β 64.8 (45.5-101.2) 52.9 (38.2-86.8) 31.9 (20.9-54.8) <0.001
Renal function indices
   Creatinine (µmol/L) 67.2 (56.1-84.6) 69.0 (52.6-80.4) 65.4 (54.8-74.0) 0.381
   eGFR (mL/min/1.73 m2) 100.3±12.5 97.7±14.9 98.3±14.8 0.834
Continuous variables were described as mean±SD for parametric variables and median (interquartile range) for nonparametric variables.
Abbreviations: T2DM, type 2 diabetes mellitus; HbA1C, glycated hemoglobin; UGE, urinary glucose excretion; UGCR, urinary glucose-to-creatinine ratio; M-
UGCR, first-voided morning spot UGCR; PCGR, postprandial C-peptide-to-glucose ratio; HOMA-IR, homeostatic model assessment of insulin resistance; 
HOMA-β, homeostatic model assessment of pancreatic β-cell function; eGFR, estimated glomerular filtration rate.
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nary glucose, sodium, albumin, and creatinine levels were also 
measured for each sample. Urinary glycemic indices were cal-
culated as follows: 1) overnight 8-hr UGE (mg)=[(overnight 8-hr 
urine glucose [mg/dL]×overnight 8-hr urine volume [mL])/100]; 
2) overnight 8-hr UGCR (mg/mg)=[overnight 8-hr urine glucose 
(mg/dL)/overnight 8-hr urine creatinine (mg/dL)]; and 3) M-UGCR 
(mg/mg)=[first-voided morning spot urine glucose (mg/dL)/first-
voided morning spot urine creatinine (mg/dL)]. We also calcu-
lated overnight 8-hr and first-voided morning spot (M-) urinary 
sodium-to-creatinine ratios (UNCRs), which showed good agree-
ment with each other in a previous study [12], for calculating 
the correlation coefficient with UGCR. Overnight 8-hr albumin-
to-creatinine ratios (ACRs) were calculated for each of the over-
night 8-hr urine samples, as [(overnight 8-hr urinary albumin 
excretion [mg/dL]/overnight 8-hr urinary creatinine excretion 
[mg/dL])×1,000] and dividing by 8.84 to convert the units (from 
mg/g to mg/mmol), to classify the participants into normo-, mi-
cro-, and macroalbuminuria groups: normoalbuminuria, over-
night 8-hr ACR<3.4 mg/mmol; microalbuminuria, 3.4 ≤over-
night 8-hr ACR<34 mg/mmol; and macroalbuminuria, over-
night 8-hr ACR ≥34 mg/mmol.
4. Statistical analyses
All statistical analyses were performed by using SPSS version 
20.0 for Windows (IBM Corp., Armonk, NY, USA) and PASS (ver-
sion 12, NCSS, LLC, Kaysville, UT, USA). The characteristics of 
the study participants were analyzed according to their diabetes 
status by a one-way ANOVA or Kruskal-Wallis test for continu-
Fig. 1. Overnight 8-hr UGE and UGCR. (A) Distribution of overnight 8-hr UGE values. Outliers of overnight 8-hr UGE above 100,000 mg (N 
= 2) were excluded in the graph. (B, C) Comparison of the correlation coefficient values between UGCRs and UNCRs.
*P <0.001; †Overnight 8-hr urinary sodium-to-creatinine ratio (UNCR)=overnight 8-hr urinary sodium excretion (mmol/L)/overnight 8-hr 
urinary creatinine excretion (mg/dL); ‡First-voided morning spot UNCR (M-UNCR)=first-voided morning spot urinary sodium excretion 
(mmol/L)/first-voided morning spot urinary creatinine excretion (mg/dL). 
Abbreviations: UGE, urinary glucose excretion; UGCR, urinary glucose-to-creatinine ratio; M-UGCR, first-voided morning spot UGCR; NGT, normal glucose 
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ous variables and a χ2 test for categorical variables. Continuous 
variables are presented as the mean±SD for normally distrib-
uted continuous variables and median (interquartile range) for 
non-normally distributed continuous variables. Categorical data 
are expressed as numbers and percentages. The correlation 
between the M-UGCR and overnight 8-hr UGCR was determined 
by calculating the Spearman’s correlation coefficient. Correlation 
statistics were interpreted as slight (0-0.2), fair (>0.2 to 0.4), 
moderate (>0.4 to 0.6), substantial (>0.6 to 0.8), and almost 
perfect (>0.8) agreement [13]. The reliability of measurements 
between the M-UGCR and overnight 8-hr UGCR was analyzed 
by calculating the intraclass correlation coefficient (ICC). A Bland-
Altman plot was used to assess the agreement between M-UGCR 
and overnight 8-hr UGCR. A Spearman’s correlation analysis 
was performed to determine the correlation between UGCRs 
and other parameters. Backward multiple linear regression anal-
ysis was performed for modeling the relationship between over-
night 8-hr UGE or M-UGCR and demographic, glycemic, insulin 
secretory/resistant, and biochemical parameters. All P values< 
0.05 were considered statistically significant.
RESULTS
1. Urinary glycemic indices of study participants
In the group with T2DM, the values of overnight 8-hr UGE showed 
a marked variation ranging from 5 mg to 151,000 mg (Fig. 1A). 
The median values of overnight 8-hr UGE in participants with 
NGT (N=14), pre-diabetes (N=41), and T2DM (N=160) were 
35.0 mg, 35.6 mg, and 653.4 mg, respectively. In participants 
with T2DM, the median values of overnight 8-hr UGCR and M-
UGCR were 1.37 mg/mg and 0.16 mg/mg, respectively. 
2. Correlation between overnight 8-hr UGCR and M-UGCR
Spearman’s correlation analyses determined that M-UGCR show ed 
an almost perfect positive relationship with overnight 8-hr UGCR 
(r=0.825, P <0.001; Fig. 1B). We also calculated overnight 
8-hr UNCR and M-UNCR, which are well known to exhibit good 
agreement with each other, for comparing the correlation coeffi-
cient with that of UGCRs [12]. The value of Spearman’s r was 
0.758 between UNCRs (P <0.001) in our study population (Fig. 
1C). Therefore, the statistical association of M-UGCR with over-
night 8-hr UGCR was stronger than that of UNCRs. ICCs were 
calculated to assess the reliability of measurements between M-
UGCR and overnight 8-hr UGCR (Table 2). The ICC value was 
0.945 (95% confidence interval [CI] 0.923-0.960; P <0.001) 
for all participants. Among diabetes status subgroups, the cor-
relation between M-UGCR and overnight 8-hr UGCR was statis-
tically significant only in T2DM (ICC=0.943, 95% CI 0.914-0.961; 
Table 2. Intraclass correlation coefficient (ICC) between the over-
night 8-hr UGCR and M-UGCR
Subgroups
ICC (95% CI) between overnight  
8-hr UGCR and M-UGCR
All participants (N=215) 0.945* (0.923-0.960)
Diabetes status
Normal glucose tolerance (N=14) 0.155 (-1.368-0.719)
Pre-diabetes (N=41) 0.049 (-0.674-0.476)
T2DM (N=160) 0.943* (0.914-0.961)
   Subgroup by albuminuria status
      Normoalbuminuria (N=111) 0.948* (0.921-0.966)
      Microalbuminuria (N=40) 0.909* (0.810-0.954)
      Macroalbuminuria (N=9) 0.989* (0.948-0.998)
   Subgroup by HbA1c, % (mmol/mol)
      <7 (<53) (N=55) 0.951* (0.914-0.972)
      7-9 (53-75) (N=67) 0.914* (0.818-0.955)
      >9 (>75) (N=38) 0.925* (0.837-0.963)
Normoalbuminuria, overnight 8-hr ACR <3.4 mg/mmol; microalbuminuria, 
3.4 ≤overnight 8-hr ACR <34 mg/mmol; macroalbuminuria, overnight 8-hr 
ACR ≥34 mg/mmol. 
*P <0.001.
Abbreviations: UGCR, urinary glucose-to-creatinine ratio; M-UGCR, first-
voided morning spot UGCR; T2DM, type 2 diabetes mellitus; HbA1C, glycat-
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Fig. 2. Bland-Altman plot for assessing the agreement between the 
overnight 8-hr UGCR and M-UGCR.
Abbreviations: UGCR, urinary glucose-to-creatinine ratio; M-UGCR, first-
voided morning spot UGCR.
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Table 3. Correlation between UGE or UGCRs and other parameters in T2DM (N=160)
Variables
Overnight 8-hr UGE Overnight 8-hr UGCR M-UGCR
r P r P r P
Demographics
   Age (yr) -0.284 <0.001 -0.224 0.004 -0.258 0.001
   Duration of diabetes (yr) 0.002 0.981 -0.018 0.827 -0.009 0.916
Glycemic indices
   Basal glucose (mmol/L) 0.646 <0.001 0.642 <0.001 0.700 <0.001
   Stimulated glucose (mmol/L) 0.690 <0.001 0.684 <0.001 0.725 <0.001
   Glycated albumin (%) 0.707 <0.001 0.695 <0.001 0.700 <0.001
   HbA1C, (%) (mmol/mol) 0.691 <0.001 0.689 <0.001 0.683 <0.001
Urinary glycemic indices
   Overnight 8-hr UGE (mg) - 0.971 <0.001 0.828 <0.001
   Overnight 8-hr UGCR (mg/mg) 0.971 <0.001 - 0.825 <0.001
   M-UGCR (mg/mg) 0.828 <0.001 0.825 <0.001 -
Insulin secretory/resistant indices
   Basal insulin (pmol/L) 0.028 0.729 0.012 0.875 -0.013 0.870
   Stimulated insulin (pmol/L) -0.305 <0.001 -0.292 <0.001 -0.365 <0.001
   Basal C-peptide (nmol/L) 0.012 0.880 -0.005 0.947 -0.028 0.731
   Stimulated C-peptide (nmol/L) -0.305 <0.001 -0.295 <0.001 -0.384 <0.001
   ∆Insulin (pmol/L) -0.379 <0.001 -0.360 <0.001 -0.432 <0.001
   ∆C-peptide (nmol/L) -0.400 <0.001 -0.379 <0.001 -0.474 <0.001
   PCGR -0.555 <0.001 -0.548 <0.001 -0.614 <0.001
   HOMA-IR 0.249 0.002 0.239 0.002 0.241 0.002
   HOMA-β -0.425 <0.001 -0.428 <0.001 -0.494 <0.001
Renal function indices
   Creatinine (µmol/L) -0.105 0.190 -0.192 0.015 -0.285 <0.001
   eGFR (mL/min/1.73 m2) 0.407 <0.001 0.390 <0.001 0.467 <0.001
Abbreviations: T2DM, type 2 diabetes mellitus; UGE, urinary glucose excretion; UGCR, urinary glucose-to-creatinine ratio; M-UGCR, first-voided morning 
spot UGCR; HbA1C, glycated hemoglobin; PCGR, postprandial C-peptide-to-glucose ratio; HOMA-IR, homeostatic model assessment of insulin resistance; 
HOMA-β, homeostatic model assessment of pancreatic β-cell function; eGFR, estimated glomerular filtration rate.
P <0.001). Moreover, regardless of the severity of albuminuria 
or glycemic control, M-UGCR and overnight 8-hr UGCR display ed 
good measurement reliability in participants with T2DM. A Bland-
Altman plot showed that M-UGCR tended to underestimate over-
night 8-hr UGCR (Fig. 2). We drew a calculation formula for 8-hr 
UGCR using M-UGCR by simple linear regression analysis. We 
propose the following formula:
   8-hr UGCR (mg/mg)=1.22×M-UGCR (mg/mg)+3.30
3.  Correlations between UGCRs and Other Parameters in T2DM
Correlations between overnight 8-hr M-UGCR and UGE, as well 
as other clinico-biochemical parameters are shown in Table 3. 
Age was negatively correlated with all UGCRs and UGE. Glyce-
mic indices, including basal and stimulated glucose, GA, and 
HbA1c, showed a substantial positive correlation with UGCRs 
and UGE. Regarding insulin secretory/resistant indices, stimu-
lated insulin and C-peptide, ∆insulin, ∆C-peptide, PCGR, and 
HOMA-β, factors associated with insulin secretory capacity, showed 
fair to substantial negative linear relationships with UGCRs and 
UGE. The value of eGFR showed a moderate positive correlation 
with UGCRs and UGE. A sample size of 160 achieved 99.9999% 
power in detecting a difference of -0.328 between the null hy-
pothesis correlation of 0.50 (derived from the previous study 
[12] for correlations between spot and 24-hr urinary sodium ex-
cretions) and the alternative hypothesis correlation of 0.828 (the 
correlation coefficient between M-UGCR and overnight 8-hr UGE) 
by a two-sided hypothesis test with a significance level of 0.05 
[14-16].
4.  Determinants of overnight 8-hr UGE or M-UGCR in T2DM 
by multiple linear regression analysis
To clarify independent relationships between clinico-biochemi-
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Table 4. Multiple linear regression models for overnight 8-hr UGE or M-UGCR in T2DM
Variables
Model 1 (Clinico-biochemical parameters) Model 2 (Insulin related parameters)
Overnight 8-hr UGE M-UGCR Overnight 8-hr UGE M-UGCR
STD β P STD β P STD β P STD β P
Demographics
   Sex, female -0.184 0.001 - - - -
Glycemic indices
   Basal glucose (mmol/L) 0.281 0.005 - - - -
   Stimulated glucose (mmol/L) 0.369 <0.001 0.161 0.094 - - - -
   GA (%) 0.380 <0.001 0.348 <0.001 - - -
Insulin secretory/resistant indices
   PCGR - - - - -0.447 <0.001 -0.458 <0.001
   HOMA-IR - - - - 0.419 <0.001 0.490 <0.001
   HOMA-β - - - - -0.331 0.001 -0.378 <0.001
Renal function indices
   eGFR (mL/min/1.73 m2) 0.122 0.036 0.153 0.006 - - - -
Logarithm-transformed values of overnight 8-hr UGE and M-UGCR were used for analysis.
Model 1: adjusted for age, sex, duration of diabetes, basal glucose, stimulated glucose, GA, HbA1C, and eGFR. 
Model 2: adjusted for PCGR, ∆Insulin, ∆C-peptide, HOMA-IR, and HOMA-β.
Bold values indicate statistical signiﬁcance.
Abbreviations: T2DM, type 2 diabetes mellitus; UGE, urinary glucose excretion; M-UGCR, first-voided morning spot urinary glucose-to-creatinine ratio; STD, 
standardized; PCGR, postprandial C-peptide-to-glucose ratio; GA, glycated albumin; HOMA-IR, homeostatic model assessment of insulin resistance; 
HOMA-β, homeostatic model assessment of pancreatic β-cell function; eGFR, estimated glomerular filtration rate; HbA1C, glycated hemoglobin.
cal variables and overnight 8-hr UGE or M-UGCR in T2DM par-
ticipants, we performed multiple linear regression analyses (Ta-
ble 4). The analyses were performed separately for two models: 
In model 1, we entered clinico-biochemical parameters, includ-
ing age, sex, duration of diabetes, basal glucose, stimulated glu-
cose, GA, HbA1c, and eGFR, as independent factors and over-
night 8-hr UGE as a dependent factor. Female sex (standard-
ized [STD] β=-0.184, P =0.001), stimulated glucose level (STD 
β=0.369, P <0.001), GA (STD β=0.380, P <0.001), and eGFR 
(STD β=0.122, P =0.036) were significantly associated with 
overnight 8-hr UGE. In model 2, with the inclusion of insulin-re-
lated parameters, such as PCGR, ∆insulin, ∆C-peptide, HOMA-
IR, and HOMA-β, the three measures PCGR (STD β=-0.447, 
P <0.001), HOMA-IR (STD β=0.419, P <0.001), and HOMA-β 
(STD β=-0.331, P =0.001) were significantly associated with 
overnight 8-hr UGE. Analyses were conducted for M-UGCR, us-
ing the same independent variables, and the patterns of M-UGCR 
regression equations were similar to those for overnight 8-hr UGE, 
except for sex.
DISCUSSION
In this study, we demonstrated that M-UGCR may be used as a 
simple index for estimating overnight UGE (8-hr UGE) in pati-
ents with T2DM. This study demonstrated three main findings: 
First, we verified that overnight 8-hr UGE or UGCR is proportion-
ally elevated with aggravated glucose tolerance. Second, with 
respect to the intra-class correlation between overnight 8-hr 
UGCR and M-UGCR, almost perfect, positive significance was 
found only in participants with T2DM, regardless of albuminuria 
stage or HbA1c levels. Third, glucose levels, beta cell response 
to stimulation, and eGFR were associated with overnight 8-hr 
UGE.
To achieve optimal glycemic control in diabetes management, 
we hypothesized that glucose monitoring in conjunction with 
HbA1c is beneficial in the context of SGLT2 inhibitor treatment. 
Influential variables affecting UGE include the circulating glu-
cose loading to the glomeruli, glomerular capacity to filter glu-
cose into the renal tubule, and albuminuria [17-19]. On the ba-
sis of previous studies [17-19], we attempted to minimize the 
effects of glomerular filtration capacity by excluding participants 
who had less than 60 mL/min/1.73 m2 of eGFR, and adjusted 
potential variables that may influence this analysis by adopting 
basal/stimulated glucose, HbA1c, and GA as glucose load to glo-
meruli and staged albuminuria (normo-, micro-, and macroal-
buminuria) classifications. As expected, the intra-class relation-
ship between 8-hr UGCR and M-UGCR was significantly corre-
lated in participants with T2DM (ICCs in NGT, pre-diabetes, and 
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T2DM were 0.155, 0.049, and 0.943, respectively). In addition, 
we attempted to outline interfering effects of glucose load on 
glomeruli and albuminuria on the relationship between 8-hr 
UGCR and M-UGCR through a subgroup analysis according to 
albuminuria status and HbA1c levels. From these subgroup anal-
yses, we found a similar correlation between 8-hr UGCR and M-
UGCR as seen in all participants with T2DM. To confer the reli-
ability of M-UGCR reflecting 8-hr UGCR, we generated a Bland-
Altman plot, which is commonly used to compare two different 
instruments or two measurement techniques that each are sus-
ceptible to some errors in their measurement. Based on analy-
sis of the Bland-Altman plot, M-UGCR tended to underestimate 
overnight 8-hr UGCR. One plausible explanation for this result 
might be a progressive decline in glucose from midnight to morn-
ing, which has been noted in continuous glucose monitoring 
system (CGMS) device data for Korean type diabetes [20-22]. 
Based on this deduction, a glucose level at the morning fasting 
time could be lower than the average overnight glucose level.
On the basis of the results of the correlation analyses for UGCRs 
and UGE in relation to clinico-biochemical variables, we per-
formed multiple linear regression analyses to predict the amount 
of 8-hr UGE or M-UGCR in participants with T2DM. Among all 
demographic factors and glycemic indices, fasting or postpran-
dial glucose levels and GA were significantly associated with 
overnight 8-hr UGE or M-UGCR. Regarding glycated protein to 
monitor average glucose excursion, the use of HbA1c as an indi-
cator of glycemic control over a 2- to 3-month period is inferior 
to GA as an intermediate glycation index over a 2- to 3-week 
period to provide the latest information on changes in glycemic 
control. Since glycemic indices are mainly dependent on insulin 
secretory beta cell function and peripheral insulin sensitivity [23], 
we also conducted a multiple linear regression analysis for these 
variables. We found that both insulin secretory function and sen-
sitivity indices were significant determinants for the amount of 
overnight 8-hr UGE or M-UGCR. Finally, by comparing UGCRs 
with UNCRs, which showed strong agreement between 8-hr and 
M-UGCRs, we confirmed the reliability of the novel methods.
Our study has some distinct strengths and potential limita-
tions. This was a rather pioneering study to verify that M-UGCR 
could be used as a simple index for estimating overnight UGE in 
only those with T2DM, which could be a potential method to 
monitor the effectiveness of SGLT2 inhibitors. Additionally, we 
performed a standardization of glucose homeostasis markers, 
including insulin secretion and sensitivity, notwithstanding stim-
ulated glucose, through a mixed meal tolerance test. Finally, by 
comparing UGCRs and UNCRs, which showed strong agree-
ment between 8-hr and M-UGCR, we conferred greater reliabil-
ity of the modified method for glucose monitoring. 
Regarding the limitations of our study, we did not demonstrate 
a clear relationship between plasma glucose concentrations and 
urinary glucose amounts, because we could not calculate renal 
threshold for glucose excretion (RTG). Since the cut-off point of 
maximum glucose reabsorption in the renal tubules (maximal 
reabsorptive capacity, TmG) is not abrupt [24], assessing RTG was 
impossible in this study design. Second, despite excluding the 
participants with less than 60 mL/min/1.73 m2 of eGFR, the glu-
cose loads into the renal tubules are also the result of glomeru-
lar filtration rate and glucose load in the glomerular capillaries. 
We did not fully control the influence of glomerular capacity to 
filter glucose into the renal tubule. Third, we did not adjust for 
the effects of anti-diabetic drugs being prescribed, which might 
have an influence on insulin secretory function, peripheral insu-
lin resistance, or gluconeogenesis, etc. Fourth, we did not col-
lect information about the time, type, and amount of the last 
meals consumed by participants, which could be one of the 
reasons why M-UGCR underestimated overnight 8-hr UGCR. 
Finally, our study did not assess differences in UGE or UGCR in 
patients treated with SGLT2 inhibitors, because no participant 
was prescribed an SGLT2 inhibitor. Further studies enrolling sub-
jects taking SGLT2 inhibitors are needed.
In conclusion, despite the relative underestimation of over-
night 8-hr UGCR by M-UGCR, these two parameters showed 
strong agreement, suggesting that M-UGCR be used as a sim-
ple index for estimating the amount of UGE occurring overnight 
in patients with T2DM. Combined monitoring of urinary glucose 
levels and blood glucose indices, including HbA1c and GA, may 
be a better indicator of glycemic control in patients who have 
been prescribed SGLT2 inhibitors. Further studies are needed 
to understand glucose homeostasis in relation to plasma and 
UGE by collecting both plasma and urinary glucose concentra-
tions for designated periods and calculating both RTG and TmG.
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